H.C. Wainwright analyst Emily Bodnar initiated coverage of Autolus Therapeutics (AUTL) with a Buy rating and $9 price target Th e firm says the company’s obecabtagene autoleucel as a “pipeline-in-a-product,” with potential to expand from rare oncology indications into treatment-refractory, B cell mediated, autoimmune diseases.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
- Autolus Therapeutics reports inducement grants under Nasdaq listing rule
- Autolus Therapeutics Signs Long-Term Lentiviral Supply Agreement
- Autolus Therapeutics price target lowered to $8 from $10 at Truist
- Autolus: Short-Term Revenue Miss, Long-Term Blockbuster Potential Supports Buy Rating